Skip to main content

Month: January 2025

Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors

World-renowned researcher brings expertise in obstetrics and gynecology from Yale University to advance Eterna’s lead indication in ovarian cancer CAMBRIDGE, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) — Eterna Therapeutics (Nasdaq: ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced the appointment of Elena Ratner, M.D., M.B.A, to the Board of Directors. Dr. Ratner will spearhead the strategic direction of Eterna’s efforts to combat ovarian cancer, leveraging her extensive expertise in obstetrics, gynecology, and reproductive sciences. Under her leadership, the company aims to accelerate advancements in innovative therapies targeting these high-priority areas in women’s health. This direction is bolstered by Eterna’s recent collaboration with MD Anderson Cancer Center. Announced last month,...

Continue reading

Novacium Partners with the French Army’s Technical Section to Develop High-Capacity Silicon-Based Batteries

The French Military is expressing interest in Novacium’s silicon-based battery technology MONTREAL, Jan. 09, 2025 (GLOBE NEWSWIRE) — HPQ Silicon Inc. (“HPQ” or the “Company”) (TSX-V: HPQ, OTCQB: HPQFF, FRA: O08), a technology company specializing in green engineering of silica and silicon-based materials, is pleased to inform its shareholders that its French-based subsidiary, NOVACIUM SAS (“Novacium”), has entered into a strategic collaboration with the French Army to develop high-capacity batteries utilizing Novacium’s silicon-based materials. Novacium’s strategic collaboration with the French Army’s Technical Section (STAT) is part of its initiative to develop prototypes of ultra-high-capacity batteries for a wide range of military applications. These include surveillance systems, electronic sights, anti-drone...

Continue reading

Form 8.3 – Ground Rents Income Fund plc

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: Jupiter Fund Management Plc(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)   Name of Offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree Ground Rents Income Fund plc(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)   Date position held:        For an opening position...

Continue reading

Gilat to Participate in the 27th Annual Needham Growth Conference on January 14, 2025

PETAH TIKVA, Israel, Jan. 09, 2025 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (Nasdaq: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, today announced management’s participation in the 27th Annual Needham Growth Conference on Tuesday, January 14, 2025. Mr. Adi Sfadia, the Company’s CEO, and Mr. Gil Benyamini, the Company’s CFO, will be available for one-on-one meetings with investors at the conference. Management will also host a fireside chat on Tuesday, January 14, 2025, at 9:30 am Eastern Time. A live webcast of the fireside chat will be available at www.gilat.com or by accessing a webcast link at https://wsw.com/webcast/needham143/gilt/2252448. To schedule a meeting with management, please contact a Needham representative or email a request to the Gilat investor relations...

Continue reading

Endeavour Silver Produces 4,471,824 Oz Silver and 39,047 Oz Gold (7.6 Million Silver Equivalent Oz) in 2024; Improved Fourth Quarter Production Delivers on Updated Annual Guidance

VANCOUVER, British Columbia, Jan. 09, 2025 (GLOBE NEWSWIRE) —  Endeavour Silver Corp. (“Endeavour” or the “Company”) (NYSE: EXK; TSX: EDR) reports full year 2024 production of 4,471,824 silver ounces (“oz”) and 39,047 gold oz, for silver equivalent(1) (“AgEq”) production of 7.6 million oz. Fourth quarter production was 824,529 silver oz and 9,075 gold oz for 1.6 million AgEq oz. “After operating at reduced capacity due to the Guanaceví trunnion failure in August, and subsequently resuming full capacity in December, we are satisfied with our production performance in Q4 and producing at the top range of our updated production guidance,” said Dan Dickson, Chief Executive Officer. “The team demonstrated exceptional diligence and commitment throughout the 15 week recovery period, ensuring the timely fabrication and...

Continue reading

Brunswick Exploration Drills 37 Meters at 1.14% Extending the MR-3 Dyke at the Mirage Project

MONTREAL, Jan. 09, 2025 (GLOBE NEWSWIRE) — Brunswick Exploration Inc. (TSX-V: BRW, OTCQB: BRWXF; FRANKFURT: 1XQ; “BRW” or the “Company”) is pleased to report the last results from the Mirage summer drilling campaign. The Mirage Project is located in the Eeyou Istchee-James Bay region of Quebec, approximately 40 kilometers south of the Trans-Taiga Road. This campaign focused on the Central Zone including the MR-6 and MR-3 dykes (see October 8, 2024 press release) and has continued to intersect wide and well-mineralized intervals on their extension and at depth. Highlights include:37 meters at 1.14% Li2O in hole MR-24-87 and 1.15% Li2O over 23 meters in hole MR-24-89 extending mineralization at MR-3 down dip where it remains open. New interval at the MR-6 Dyke with 1.74% Li2O over 19.7 meters in hole MR-24-84 and 0.93% Li2O over...

Continue reading

Ultimovacs ASA: Notification of major holdings

Oslo, 9 January 2025: Reference is made to the stock exchange notices published by Ultimovacs ASA (the “Company“) on (i) 17 December 2024 regarding the contemplated business combination between the Company and Zelluna Immunotherapy AS (the “Business Combination“) and the fully committed private placement with gross proceeds of approx. NOK 51.7 million (the “Private Placement“) and (ii) today on 9 January 2025 regarding the approval by an extraordinary general meeting of the Company (the “EGM“) of relevant resolutions related to the Business Combination and the Private Placement. The Business Combination and the Private Placement are hereinafter referred to as the “Transactions“. Following the EGM’s resolutions to approve the issuance of 167,864,598 shares in aggregate through...

Continue reading

Teleflex awarded Short Term Central Venous Catheters contract from Vizient

Including market leading Arrow™ CVCs and Arterial Catheters WAYNE, Pa., Jan. 09, 2025 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has been awarded a contract by Vizient, Inc., the largest provider-driven healthcare performance improvement company in the U.S. The agreement, effective January 1, 2025, covers the supply of Teleflex’s Central Venous Access Catheters and Arterial Catheters. Vizient provides solutions and services that improve the delivery of high-value care by aligning cost, quality, and market performance for more than 65% of the nation’s acute care providers. This includes 97% of the nation’s academic medical centers, and more than 35% of the acute care market. Vizient provides expertise, analytics, and advisory services, as well...

Continue reading

Kaldalón hf.: Announcement from the Nomination Committee

The Nomination Committee of Kaldalón serves an advisory role in the selection of the Company’s Board of Directors and nominates candidates for board positions. Further details on the role of the Nomination Committee and its rules of procedure are available on Kaldalón’s website. The Nomination Committee of Kaldalón invites proposals for board members or declarations of candidacy for the upcoming Annual General Meeting of the company, scheduled for April 3, 2025. The committee requests that such information will be sent to the committee’s email address, tilnefningarnefnd@kaldalon.is, by 4:00 PM on January 31, 2025. Candidacies must include information on the candidacy form, which can be found on Kaldalón’s website. The above deadline does not restrict candidates’ right to submit candidacies within the timeframe stipulated...

Continue reading

Form 8.3 – [LOUNGERS PLC – 08 01 2025] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary Clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree LOUNGERS PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.